Trials / Active Not Recruiting
Active Not RecruitingNCT04072458
A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies
A Phase 1 Clinical Trial to Study the Safety, Pharmacokinetics, and Efficacy of BP1002 (L-Bcl-2) Antisense Oligonucleotide in Patients With Advanced Lymphoid Malignancies
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Bio-Path Holdings, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates the safety, pharmacokinetics, and efficacy of BP1002 (L-Bcl-2) antisense oligonucleotide in patients with advanced lymphoid malignancies. Up to 12 evaluable patients with a diagnosis of relapsed or refractory lymphoid malignancies are expected to participate.
Conditions
- Mantle Cell Lymphoma
- Peripheral T-cell Lymphoma (PTCL)
- Cutaneous T-cell Lymphoma (CTCL)
- Chronic Lymphocytic Leukemia (CLL)
- Small Lymphocytic Lymphoma (SLL)
- Follicular Lymphoma
- Marginal Zone Lymphoma
- Hodgkin Lymphoma
- Waldenstrom Macroglobulinemia
- DLBCL
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | L-Bcl-2 antisense oligonucleotide | There will be 2 planned dose levels, 20, and 40 mg/m\^2. Successive cohorts of eligible patients with will be treated with BP1002. BP1002 is given as an intravenous infusion, twice weekly, as 8 doses per 28-day cycle. Cycles may be repeated every 4 weeks. |
Timeline
- Start date
- 2020-11-05
- Primary completion
- 2025-04-01
- Completion
- 2025-04-01
- First posted
- 2019-08-28
- Last updated
- 2025-02-24
Locations
5 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04072458. Inclusion in this directory is not an endorsement.